Sachdev, Jasgit C. http://orcid.org/0000-0002-4408-7617
Munster, Pamela
Northfelt, Donald W.
Han, Hyo Sook
Ma, Cynthia
Maxwell, Fiona
Wang, Tiffany
Belanger, Bruce
Zhang, Bin
Moore, Yan
Thiagalingam, Arunthathi
Anders, Carey
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
https://doi.org/10.1007/s10549-020-05995-7
Funding for this research was provided by:
Ipsen Biopharmaceuticals
Article History
Received: 15 July 2020
Accepted: 20 October 2020
First Online: 17 November 2020
Compliance with ethical standards
:
: Jasgit C. Sachdev has received research funding from Celgene, Genentech, and Pfizer; compensation for the role of adviser from Celgene, Ipsen, Novartis, Pfizer, Puma Biotechnology, TapImmune, Tempus, and TTC Oncology; and honorarium from Celgene, Ipsen, Novartis, Pfizer, Puma Biotechnology, and Tempus. Hyo Sook Han has received research funding from AbbVie, Bristol Myers Squibb, the Department of Defense, Horizon Therapeutics, Ipsen, Karyopharm Therapeutics, Novartis, Pfizer, Prescient, Seattle Genetics, TapImmune, and Tesaro; and compensation for a speaker’s bureau from Eli Lilly. Cynthia Ma has received research funding from Pfizer, Puma Biotechnology, and Tempus; compensations for a consulting role for Agendia, AstraZeneca, Eli Lilly, Novartis, OncoSignal, Pfizer, Seattle Genetics, and Tempus. Fiona Maxwell, Tiffany Wang, Bruce Belanger, Bin Zhang, Yan Moore, and Arunthathi Thiagalingam are employees of Ipsen and hold stock or stock options. Carey Anders has received research funding from Eli Lilly, G1-Therapeutics, Merck, Nektar Technology, Puma Biotechnology, Seattle Genetics, and Tesaro; compensation for a consultant role from Eisai, Genentech, Ipsen, Puma Biotechnology, and Seattle Genetics; and royalties from Jones & Bartlett Learning and UpToDate. Pamela Munster and Donald W. Northfelt have nothing to disclose.